ATNM · Insider Trading
Actinium Pharmaceuticals, Inc
Every open-market purchase and sale reported by ATNM officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-16 | Matthew T David | Chief Financial Officer | A | +250,000 | — |
| 2026-09-04 | Sandesh Seth | Chief Executive Officer | A | +1,780,874 | — |
| 2026-09-04 | Richard I Steinhart | Director | A | +62,800 | — |
| 2026-09-04 | June Sherie Almenoff | Director | A | +18,000 | — |
| 2026-09-04 | Jeffrey W. Chell | Director | A | +61,600 | — |
| 2026-09-04 | Ajit Shetty | Director | A | +61,600 | — |
| 2026-09-04 | C. David Nicholson | Director | A | +62,800 | — |
| 2025-08-20 | Sandesh Seth | Chief Executive Officer | F | −120,900 | −$206.74K |
| 2025-04-02 | June Sherie Almenoff | Director | D | −50,000 deriv. | — |
| 2025-04-02 | Ajit Shetty | Director | D | −182,484 deriv. | — |
| 2025-04-02 | Richard I Steinhart | Director | D | −184,984 deriv. | — |
| 2025-04-02 | Jeffrey W. Chell | Director | D | −182,484 deriv. | — |
| 2025-04-02 | Sandesh Seth | Chief Executive Officer | D | −2,385,976 deriv. | — |
| 2025-04-02 | C. David Nicholson | Director | D | −184,984 deriv. | — |
| 2025-04-02 | Steve O'Loughlin | Chief Financial Officer | D | −706,588 deriv. | — |
| 2024-11-05 | June Sherie Almenoff | Director | A | +50,000 deriv. | — |
| 2023-12-29 | Ajit Shetty | Director | A | +70,311 deriv. | — |
| 2023-12-29 | C. David Nicholson | Director | A | +70,311 deriv. | — |
| 2023-12-29 | Jeffrey W. Chell | Director | A | +70,311 deriv. | — |
| 2023-12-29 | Steve O'Loughlin | Chief Financial Officer | A | +253,123 deriv. | — |
| 2023-12-29 | Richard I Steinhart | Director | A | +70,311 deriv. | — |
| 2023-12-29 | Sandesh Seth | Chief Executive Officer | A | +984,367 deriv. | — |
| 2022-08-19 | Sandesh Seth | Chief Executive Officer | A | +300,000 | — |
| 2022-07-01 | Steve O'Loughlin | Chief Financial Officer | A | +256,438 deriv. | — |
| 2022-07-01 | Richard I Steinhart | Director | A | +72,156 deriv. | — |
| 2022-07-01 | Sandesh Seth | Chief Executive Officer | A | +827,366 deriv. | — |
| 2022-07-01 | C. David Nicholson | Director | A | +72,156 deriv. | — |
| 2022-07-01 | Ajit Shetty | Director | A | +72,156 deriv. | — |
| 2022-07-01 | Jeffrey W. Chell | Director | A | +72,156 deriv. | — |
| 2021-09-03 | C. David Nicholson | Director | A | +18,351 deriv. | — |
| 2021-09-03 | Mark Stanley Berger | Chief Medical Officer | A | +67,164 deriv. | — |
| 2021-09-03 | Ajit Shetty | Director | A | +18,351 deriv. | — |
| 2021-09-03 | Jeffrey W. Chell | Director | A | +18,351 deriv. | — |
| 2021-09-03 | Steve O'Loughlin | Chief Financial Officer | A | +107,463 deriv. | — |
| 2021-09-03 | Richard I Steinhart | Director | A | +18,351 deriv. | — |
| 2021-09-03 | Sandesh Seth | Chief Executive Officer | A | +310,182 deriv. | — |
| 2020-08-14 | Richard I Steinhart | Director | A | +8,333 deriv. | — |
| 2020-08-14 | Ajit Shetty | Director | A | +8,333 deriv. | — |
| 2020-08-14 | Jeffrey W. Chell | Director | A | +8,333 deriv. | — |
| 2020-08-14 | Sandesh Seth | Chief Executive Officer | A | +139,062 deriv. | — |
| 2020-08-14 | C. David Nicholson | Director | A | +8,333 deriv. | — |
| 2020-08-14 | Mark Stanley Berger | Chief Medical Officer | A | +46,667 deriv. | — |
| 2020-08-14 | Dale L. Ludwig | Chief Science & Tech. Officer | A | +50,000 deriv. | — |
| 2020-08-14 | Steve O'Loughlin | Chief Financial Officer | A | +59,066 deriv. | — |
| 2019-07-16 | C. David Nicholson | Director | A | +250,000 deriv. | — |
| 2019-07-16 | Mark Stanley Berger | Chief Medical Officer | A | +400,000 deriv. | — |
| 2019-07-16 | Ajit Shetty | Director | A | +250,000 deriv. | — |
| 2019-07-16 | Dale L. Ludwig | Chief Scientific Officer | A | +400,000 deriv. | — |
| 2019-07-16 | Steve O'Loughlin | Principal Financial Officer | A | +400,000 deriv. | — |
| 2019-07-16 | Anil Kapur | Chief Commercial Officer | A | +400,000 deriv. | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Sandesh Seth | Chief Executive Officer | 938,081 | $1.31M |
| Matthew T David | Chief Financial Officer | 250,000 | $350.00K |
| C. David Nicholson | Director | 63,300 | $88.62K |
| Richard I Steinhart | Director | 63,116 | $88.36K |
| Ajit Shetty | Director | 62,357 | $87.30K |
| Jeffrey W. Chell | Director | 61,600 | $86.24K |
| June Sherie Almenoff | Director | 18,000 | $25.20K |
| Steve O'Loughlin | Chief Financial Officer | 1,183 | $1.66K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the ATNM quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.